Skip to content

Implementation of a Pediatric-to-adult Asthma Transition Program

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01521247
Enrollment
30
Registered
2012-01-30
Start date
2010-04-30
Completion date
2015-07-31
Last updated
2016-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma, Education

Keywords

Asthma, Transition program, Pediatric, Adult

Brief summary

Despite the clear and often stated need, a formal transition program does not exist for asthma patients as they move from pediatric to adult care in Western Canada. This population is not having their health care needs met. The investigators proposed study would evaluate a well structured transition program designed to facilitate continuity of care for this at risk patient population. Primary hypothesis: A pediatric-to-adult asthma transition program will improve the asthma-specific quality of life of young asthma patients in the Calgary area over a 1 year period. Secondary hypothesis: A pediatric-to-adult asthma transition program will improve asthma control, decrease asthma exacerbations, and reduce health care utilization in young asthma patients in the Calgary area over a 1 year period.

Interventions

OTHERAsthma Transition Program

Asthma Education.

Sponsors

University of Calgary
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
17 Years to 19 Years
Healthy volunteers
No

Inclusion criteria

* clinical diagnosis of asthma (as confirmed by a pediatric respirologist or pediatrician with asthma expertise, and including evidence of variable airflow obstruction, bronchial hyperresponsiveness, airway inflammation, and/or response to therapy)

Exclusion criteria

* patients who are known to be non-adherent within the Calgary Regional Pediatric Asthma Clinic (defined as \>50% missed appointments over a 2 year period) * patients unable to complete pulmonary function testing * patients with a history of significant respiratory comorbid conditions (including history of cystic fibrosis, alpha-1 antitrypsin deficiency, and lung transplant - rhinosinusitis patients will not be excluded) * patients unable to provide consent.

Design outcomes

Primary

MeasureTime frameDescription
Asthma Quality of Life Questionnaire with Standardized Activities [AQLQ(S)]12 monthsAQLQ(S) will be recorded at baseline, 6 months, and 12 months. The primary outcome will be the change in AQLQ(S) from baseline to 12 months.

Secondary

MeasureTime frameDescription
Asthma Control Questionnaire (ACQ)12 monthsThe ACQ will be administered at baseline, 6 months, and 12 months. The secondary outcome will assess change in ACQ from baseline to 12 months.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026